Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Immunology

Figure 3

From: Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity

Figure 3

Survival of vaccinated mice challenged i.p. with 5 × 105viable B16F1 tumor cells. Mice were immunized with tumor vaccine composed of 1 × 106 B16F1 irradiated tumor cells and 30 μg of CpG ODNs, followed by two additional injections of 30 μg of CpG ODNs 2 and 4 days after tumor vaccine application. The tumor vaccine was first applied on day 90, day 60 or day 30 prior to viable tumor cell inoculation (day 0). The tumor vaccine was administrated once (1×), twice (2×) and three times (3×) in 15 days period. Control: mock treated; 1 × 90: vaccine + two additional injections of CpG ODNs applied once 90 days before tumor inoculation; 2 × 90: vaccine + two additional injections of CpG ODNs applied twice 90 and 75 days before tumor inoculation; 3 × 90: vaccine + two additional injections of CpG ODNs applied three times 90, 75 and 60 days before tumor inoculation; 1 × 60: vaccine + two additional injections of CpG ODNs applied once 60 days before tumor inoculation; 2 × 60: vaccine + two additional injections of CpG ODNs applied twice 60 and 45 days before tumor inoculation; 3 × 60: vaccine + two additional injections of CpG ODNs applied three times 60, 45 and 30 days before tumor inoculation; 1 × 30: vaccine + two additional injections of CpG ODNs applied once 30 days before tumor inoculation; 2 × 30: vaccine + two additional injections of CpG ODNs applied twice 30 and 15 days before tumor inoculation; 3 × 30: vaccine + two additional injections of CpG ODNs applied three times 30, 15 and 7 days before tumor inoculation. The experiment was repeated three times.

Back to article page